The biotech company Opexa announced today that its president and CEO, Neil K. Warma, will deliver a corporate presentation of its patient-specific therapies that are targeted for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes. The presentation will be at Rodman & Renshaw’s 10th Annual Health Care Conference in New York City and will include an overview of the company’s ongoing development program for Tovaxin which is an individualized T-cell therapeutic vaccine that is being developed for the treatment of MS, and which recently yielded positive data from a Phase IIb clinical trial in which 150 patients participated in the multi-center, randomized, double blind, placebo controlled study for the treatment of the Relapsing-Remitting (RR) form of multiple sclerosis. Among other measurements, MRI scans showed statistically significant decreased lesions in those patients who had received Tovaxin.
Tovaxin, which requires only 5 subcutaneous injections per year, is an individualized T-cell therapeutic vaccine based upon attenuated patient-specific myelin-reactive T-cells against peptides of protein from myelin basic protein, myelin oligodendrocyte glycoprotein and proteolipid protein or combinations thereof. Tovaxin is manufactured in Opexa’s in-house cGMP facility.
Tovaxin’s dual mechanism of action combats the demyelination of the nerve fibers in the central nervous system, which is the underlying cause of MS. Clinical results have demonstrated that Tovaxin induces an immune response that depletes and regulates the circulating pathogenic myelin-reactive T-cells that are responsible for attacking the myelin sheath of nerve fibers. Additionally, Tovaxin also rebalances the systemic immune response by causing a shift from pathogenic inflammatory T-cells to anti-inflammatory T-cells.
Opexa Therapeutics is focused on the development and commercialization of patient-specific autologous (in which the donor and recipient are the same person) cellular therapies that are based upon proprietary T-cell and adult stem cell products for the treatment of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and diabetes. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood, which allow large quantities of monocyte-derived stem cells to be produced efficiently for use in autologous therapy, thereby eliminating the risk of immune rejection. In addition to Tovaxin, the T-cell therapy for MS which is currently in Phase IIb clinical trials, Opexa is also in the preclinical development of another product for diabetes mellitus.
